MNOV
Price
$1.40Alerts
Change
-$0.01 (-0.71%)
Updated
Nov 12 closing price
Capitalization
71.86M
98 days until earnings call
Intraday BUY SELL Signals
NCEL
Price
$2.69Alerts
Change
-$0.11 (-3.93%)
Updated
Nov 12 closing price
Capitalization
15.94M
Intraday BUY SELL Signals
Interact to see
Advertisement

MNOV vs NCEL

MNOV vs NCEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MNOV vs. NCEL commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNOV is a Hold and NCEL is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MNOV with price predictions
Nov 12, 2026

MNOV's Stochastic Oscillator remains in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Oscillator exited the oversold zone, 20 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Momentum Indicator moved above the 0 level on November 12, 2026. You may want to consider a long position or call options on MNOV as a result. In 63 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on October 28, 2026. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.

Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in 129 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

Bearish Trend Analysis

The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for MNOV entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.928) is normal, around the industry mean (3.498). P/E Ratio (-6.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NCEL with price predictions
Nov 12, 2026

NCEL saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for NCEL moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 38 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for NCEL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

NCEL broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NCEL entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NCEL's RSI Oscillator exited the oversold zone, 35 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on NCEL as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for NCEL just turned positive on November 03, 2026. Looking at past instances where NCEL's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.

Following a +11.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCEL advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. NCEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (4.929) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
MNOV: Fundamental Ratings
MNOV
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
57
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MNOVNCEL
RSI
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
67%
Bullish Trend 24 days ago
84%
Declines
ODDS (%)
Bearish Trend 25 days ago
79%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (MNOV: $1.40 vs. NCEL: $2.69)
Brand notoriety: MNOV and NCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNOV: 2% vs. NCEL: 82%
Market capitalization -- MNOV: $71.86M vs. NCEL: $15.94M
MNOV [@Biotechnology] is valued at $71.86M. NCEL’s [@Biotechnology] market capitalization is $15.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNOV’s FA Score shows that 1 FA rating(s) are green while NCEL’s FA Score has 0 green FA rating(s).

  • MNOV’s FA Score: 1 green, 4 red.
  • NCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, MNOV is a better buy in the long-term than NCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNOV’s TA Score shows that 5 TA indicator(s) are bullish while NCEL’s TA Score has 4 bullish TA indicator(s).

  • MNOV’s TA Score: 5 bullish, 3 bearish.
  • NCEL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MNOV is a better buy in the short-term than NCEL.

Price Growth

MNOV (@Biotechnology) experienced а -3.45% price change this week, while NCEL (@Biotechnology) price change was -6.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.

Reported Earning Dates

MNOV is expected to report earnings on Feb 19, 2027.

Industries' Descriptions

@Biotechnology (+2.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

MNOV and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with FATE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
-0.71%
FATE - MNOV
36%
Loosely correlated
-16.51%
NCEL - MNOV
36%
Loosely correlated
-3.93%
VIR - MNOV
29%
Poorly correlated
-7.69%
IMA - MNOV
28%
Poorly correlated
-9.92%
TIL - MNOV
28%
Poorly correlated
-1.11%
More

NCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCEL has been loosely correlated with APVO. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NCEL jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCEL
1D Price
Change %
NCEL100%
-3.93%
APVO - NCEL
63%
Loosely correlated
-13.14%
CANF - NCEL
62%
Loosely correlated
-3.87%
MLEC - NCEL
58%
Loosely correlated
N/A
IRON - NCEL
54%
Loosely correlated
-4.42%
RANI - NCEL
46%
Loosely correlated
-7.54%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EYES28.67N/A
N/A
Corgi Data & Surveillance ETF (EYES)
FJUL61.09-0.13
-0.21%
FT Vest U.S. Equity Buffer ETF - July (FJUL)
NMBL20.23-0.08
-0.37%
NovaTide Flexible Allocation ETF (NMBL)
VBCD73.44-0.30
-0.40%
Vanguard Target Maturity 2030 Corporate Bond ETF (VBCD)
PBW25.64-1.23
-4.58%
Invesco WilderHill Clean Energy ETF (PBW)